Summary of Significant Accounting Policies (Details Narrative)
|
|
|
|
|
1 Months Ended |
3 Months Ended |
6 Months Ended |
12 Months Ended |
|
|
|
May 22, 2026
USD ($)
$ / shares
shares
|
Mar. 25, 2026
USD ($)
|
Sep. 11, 2025
USD ($)
$ / shares
shares
|
Jun. 03, 2025
USD ($)
|
Dec. 31, 2025
USD ($)
$ / shares
shares
|
Jun. 30, 2026
USD ($)
$ / shares
shares
|
Mar. 31, 2026
USD ($)
|
Jun. 30, 2025
USD ($)
shares
|
Mar. 31, 2025
USD ($)
|
Jun. 30, 2026
USD ($)
Segment
$ / shares
shares
|
Jun. 30, 2025
USD ($)
shares
|
Dec. 31, 2025
USD ($)
$ / shares
shares
|
Jun. 30, 2026
AUD ($)
|
Jul. 25, 2024
USD ($)
|
| Property, Plant, and Equipment [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of reportable segments | Segment |
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
| Number of operating segments | Segment |
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
| Net loss |
|
|
|
|
|
$ 11,557,002
|
$ 10,086,687
|
$ 6,622,563
|
$ 4,542,528
|
$ 21,643,689
|
$ 11,165,091
|
$ 29,400,000
|
|
|
| Accumulated deficit |
|
|
|
|
$ 104,463,284
|
126,106,973
|
|
|
|
126,106,973
|
|
$ 104,463,284
|
|
|
| Grants receivable on reimbursement |
|
|
|
|
|
6,700,000
|
|
|
|
6,700,000
|
|
|
|
$ 8,000,000.0
|
| Grants receivable |
|
|
|
|
|
500,000
|
|
0
|
|
2,000,000.0
|
1,700,000
|
|
|
|
| Grants receivable based on achievement of milestones |
|
|
|
|
|
1,300,000
|
|
|
|
$ 1,300,000
|
|
|
|
|
| Shares issued value |
|
|
|
|
|
140,722,254
|
|
|
|
|
|
|
|
|
| Shares issued under ATM facility, value |
|
|
|
|
|
$ 13,943,659
|
|
1,094,399
|
|
|
|
|
|
|
| Common stock, par value | $ / shares |
|
|
|
|
$ 0.0001
|
$ 0.0001
|
|
|
|
$ 0.0001
|
|
$ 0.0001
|
|
|
| Share price | $ / shares |
$ 8.94
|
|
|
|
$ 5.10
|
|
|
|
|
|
|
$ 5.10
|
|
|
| Cash and cash equivalents and short term invesrments |
|
|
|
|
|
$ 232,100,000
|
|
|
|
$ 232,100,000
|
|
|
|
|
| Cash and cash equivalents and long term invesrments |
|
|
|
|
|
2,052,142
|
|
|
|
2,052,142
|
|
|
|
|
| FDIC insured amount |
|
|
|
|
|
250,000
|
|
|
|
250,000
|
|
|
$ 250,000
|
|
| Short-Term Investments |
|
|
|
|
6,480,860
|
6,615,168
|
|
|
|
6,615,168
|
|
6,480,860
|
|
|
| Research and development expense |
|
|
|
|
|
5,333,172
|
|
3,972,458
|
|
11,313,649
|
5,947,532
|
|
|
|
| Income taxes receivable |
|
|
|
|
0
|
0
|
|
|
|
0
|
|
0
|
|
|
| Deferred offering costs |
|
|
|
|
$ 93,630
|
0
|
|
|
|
0
|
|
$ 93,630
|
|
|
| Foreign currency transaction gains and losses |
|
|
|
|
|
$ 9,271
|
|
$ 5,232
|
|
$ 14,273
|
$ 16,884
|
|
|
|
| Filer category description |
|
|
|
|
|
|
|
|
|
The
Company currently expects to continue to qualify as both a Smaller Reporting Company under Rule 12b-2 of the Exchange Act and a Non-Accelerated
Filer, based on its annual revenues of less than $100 million and public float of less than $700 million, for the foreseeable future. Accordingly, following the
loss of emerging growth company status, the Company expects to remain eligible for certain scaled disclosure and other reporting accommodations
available to smaller reporting companies and non-accelerated filers, including reduced executive compensation disclosure requirements
and the exemption from the requirement to obtain an auditor attestation report on the effectiveness of internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002, so long as it continues to satisfy the applicable eligibility criteria.
|
|
|
|
|
| Stock Options and Warrants Exercisable [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Property, Plant, and Equipment [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antidilutive securities excluded from computation of earnings per share, amount | shares |
|
|
|
|
|
9,773,316
|
|
9,773,316
|
|
9,773,316
|
9,773,316
|
|
|
|
| Stock Options and Warrants Exercisable One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Property, Plant, and Equipment [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antidilutive securities excluded from computation of earnings per share, amount | shares |
|
|
|
|
|
5,338,448
|
|
5,338,448
|
|
5,338,448
|
5,338,448
|
|
|
|
| Australian Tax Incentive [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Property, Plant, and Equipment [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Research and development expense |
|
|
|
|
|
$ 365
|
|
$ 0
|
|
$ 76,769
|
$ 124
|
|
|
|
| Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Property, Plant, and Equipment [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares issued value |
|
|
|
|
|
$ 1,678
|
|
|
|
|
|
|
|
|
| Shares issued under ATM facility | shares |
|
|
|
|
|
1,510,000
|
|
513,935
|
|
|
|
|
|
|
| Shares issued under ATM facility, value |
|
|
|
|
|
$ 151
|
|
$ 51
|
|
|
|
|
|
|
| Number of shares sold in public offering | shares |
16,778,524
|
|
|
|
19,117,646
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Prefunded Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Property, Plant, and Equipment [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price, per share | $ / shares |
|
|
|
|
|
$ 0.0001
|
|
|
|
$ 0.0001
|
|
|
|
|
| Underlying pre-funded warrants | shares |
|
|
|
|
|
2,403,857
|
|
1,913,661
|
|
2,403,857
|
1,913,661
|
|
|
|
| Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Property, Plant, and Equipment [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issuance of warrants | shares |
|
|
2,936,709
|
|
|
|
|
|
|
|
|
|
|
|
| PreFunded Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Property, Plant, and Equipment [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds of common stock |
$ 140,700,000
|
|
|
|
$ 93,700,000
|
|
|
|
|
|
|
|
|
|
| Shares issued | shares |
|
|
|
|
490,196
|
|
|
|
|
|
|
490,196
|
|
|
| Exercise price, per share | $ / shares |
|
|
|
|
$ 5.09
|
|
|
|
|
|
|
$ 5.09
|
|
|
| June 2025 ATM Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Property, Plant, and Equipment [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares issued value |
|
|
|
$ 50,000
|
|
|
|
|
|
|
|
|
|
|
| Commission rate |
|
|
|
3.00%
|
|
|
|
|
|
|
|
|
|
|
| Shares issued under ATM facility | shares |
|
|
|
|
|
1,510,000
|
|
|
|
|
|
|
|
|
| Shares issued under ATM facility, value |
|
|
|
|
|
$ 13,943,659
|
|
|
|
|
|
|
|
|
| June 2025 ATM Agreement [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Property, Plant, and Equipment [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares issued value |
|
$ 50,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| June 2025 ATM Agreement [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Property, Plant, and Equipment [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares issued value |
|
$ 100,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| June 2025 ATM Agreement [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Property, Plant, and Equipment [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares issued value |
|
|
|
$ 50,000,000
|
|
|
|
|
|
|
|
|
|
|
| Citizens ATM Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Property, Plant, and Equipment [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares sold | shares |
|
|
|
|
|
|
|
|
|
1,510,000
|
|
|
|
|
| Net proceeds of common stock |
|
|
|
|
|
|
|
|
|
$ 13,943,659
|
|
|
|
|
| Citizens ATM Agreement [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Property, Plant, and Equipment [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares sold | shares |
|
|
|
|
|
|
|
|
|
3,207,504
|
|
|
|
|
| Net proceeds of common stock |
|
|
|
|
|
|
|
|
|
$ 18,353,089
|
|
|
|
|
| Securities Purchase Agreements [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Property, Plant, and Equipment [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock, par value | $ / shares |
|
|
$ 0.0001
|
|
|
|
|
|
|
|
|
|
|
|
| Share price | $ / shares |
|
|
$ 2.37
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from private placement |
|
|
$ 9,300,000
|
|
|
|
|
|
|
|
|
|
|
|
| Share price | $ / shares |
|
|
$ 2.00
|
|
|
|
|
|
|
|
|
|
|
|
| Securities Purchase Agreements [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Property, Plant, and Equipment [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issuance of shares | shares |
|
|
3,915,604
|
|
|
|
|
|
|
|
|
|
|
|
| Securities Purchase Agreements [Member] | Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Property, Plant, and Equipment [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issuance of warrants | shares |
|
|
2,936,709
|
|
|
|
|
|
|
|
|
|
|
|
| Immix Biopharma Australia Pty Ltd. [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Property, Plant, and Equipment [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Non-controlling interest rate |
|
|
|
|
|
100.00%
|
|
|
|
100.00%
|
|
|
100.00%
|
|